CPT 78816 Denials: A Coding and Appeal Guide for Whole-Body PET/CT

Start by Confirming the Code

CPT 78816 is a tumor imaging code. It reports a PET scan of the whole body done on a combined PET/CT scanner, with a CT taken in the same session so the PET images can be corrected and findings can be placed on the anatomy. What separates it from 78814 and 78815 is the field of view. What separates it from 78813 is the same-session CT.

It is one of six tumor PET codes:

Two checks before you spend time on an appeal:

• If the scan covered skull base to mid-thigh, the code is 78815, not 78816. A 78816 claim should be backed by a report that documents a whole-body field of view and a chart note that explains why that field was needed. If the report does not support it, correct the claim instead of appealing it.
• If your denial is for a nuclear stress test, 78816 is not your code. SPECT myocardial perfusion imaging is reported with 78451 (single study) or 78452 (multiple studies, such as rest and stress). Cardiac PET is reported with 78429 to 78434, 78459, 78491 or 78492. Work that denial under the payer's cardiac imaging policy, and for Traditional Medicare, your MAC's LCD or billing article for cardiac nuclear imaging if it has one.

Common Reasons 78816 Is Denied

1. PI or PS Modifier Missing (Traditional Medicare)

Medicare requires one of two modifiers on a tumor PET or PET/CT claim. PI means the scan informs the initial treatment strategy for a tumor that is biopsy-proven or strongly suspected based on other testing. PS means it informs the subsequent treatment strategy after initial therapy. Under the Medicare Claims Processing Manual, Chapter 13, section 60.16, a claim without the right modifier is returned as unprocessable with CARC 4 (procedure code inconsistent with the modifier used) and RARC MA130. MA130 means that claim has no appeal rights. Add the modifier and submit a new claim.

2. Tracer Code Missing or Wrong

Chapter 13, sections 60.3.1 and 60.3.2, require a radiopharmaceutical (tracer) code on every PET claim alongside the scan code. For F-18 FDG, the HCPCS code is A9552. If the tracer line is missing, correct the claim. If the scan used a tracer other than FDG, make sure the code billed matches the tracer actually given, because the Medicare frequency and coverage rules in the next two sections are written for FDG.

3. More Than Three Scans for Subsequent Treatment Strategy

NCD 220.6.17 nationally covers one FDG PET study to inform initial treatment strategy and three FDG PET scans to guide subsequent treatment strategy after initial anti-cancer therapy is complete. Coverage of a fourth or later subsequent scan for the same cancer is decided by the MAC, and the claim must carry the KX modifier to show the coverage criteria are met.

Without KX, Chapter 13, section 60.16 directs a denial with CARC 96 (non-covered charges) and RARC N435 (number or frequency allowed within the time period exceeded without supporting documentation). The group code is CO, or PR when the claim carries a GA modifier because a signed ABN is on file. A different cancer diagnosis starts a new count.

The limit applies to the patient, not to your facility, so scans billed elsewhere for the same cancer can count toward the three. Ask the ordering physician and the patient about PET scans done at other facilities. If the scan meets your MAC's criteria and KX was simply left off, check your MAC's reopening guidance: a party may request a reopening within one year of the initial determination for any reason (42 CFR 405.980). Otherwise, file a redetermination with the documentation.

4. The Indication Is Not Covered

NCD 220.6.17 nationally non-covers some initial-strategy uses of FDG PET: initial treatment strategy for adenocarcinoma of the prostate, initial diagnosis or axillary node staging in breast cancer, regional lymph node evaluation in melanoma, and initial diagnosis of cervical cancer. A denial on one of these indications is a coverage decision, not a documentation gap. Before appealing, confirm the order and diagnosis codes reflect the actual clinical question, and check whether an ABN was signed.

5. Prior Authorization Absent or Not Matching (CARC 197)

Medicare Advantage, Medicaid managed care and commercial plans may require prior authorization for PET/CT, and some route those requests through a radiology benefit management vendor. Check two things: whether an authorization existed at all, and whether it matches what was billed. An authorization for 78815 may not cover a 78816 claim. If the field of view changed on the day of the scan, ask whether the plan will update the authorization before you appeal.

From January 1, 2026, CMS-0057-F requires Medicare Advantage plans and state Medicaid and CHIP programs (fee-for-service and managed care) to decide standard prior authorization requests within 7 calendar days and expedited ones within 72 hours, and to give a specific reason for a denial. The rule does not cover ordinary employer or commercial plans. When you get a specific reason, that is what the appeal has to answer.

6. Medical Necessity (CARC 50)

Commercial plans apply their own medical policies and imaging guidelines. Medicare Advantage plans must follow national coverage determinations (42 CFR 422.101(b)(1)) and may apply their own published criteria only where Medicare coverage criteria are not fully established (422.101(b)(6)). Get the policy or guideline the plan applied (the denial notice should name it) and answer each criterion with a citation to the chart. Some guidelines limit whole-body PET/CT to particular cancers or clinical questions, so the chart's reason for the whole-body field matters.

7. Diagnostic CT Billed With 78816

The Medicare NCCI Policy Manual, Chapter IX sets the rules:

• The CT used for attenuation correction and localization is never billed separately with 78811 to 78816.
• A medically necessary diagnostic CT can be billed separately with an NCCI PTP-associated modifier.
• If the diagnostic CT data come from the same acquisition on the integrated PET/CT scanner, with the CT co-registered to the PET for attenuation correction and localization, bill the PET with a PET-only code (78811 to 78813) and the diagnostic CT code with the modifier. In that case the diagnostic CT code is not reported with 78814 to 78816.
• If the diagnostic CT is a separate data set, obtained separately from the PET/CT data set, the diagnostic CT code may be reported with 78816 using the modifier. The chapter's Nuclear Medicine section says the data sets must be obtained separately; its General Policy Statements section says on separate pieces of equipment. Document how the diagnostic CT was acquired, especially if both data sets came from the same scanner.

If the report shows one combined acquisition and the CT line was denied, correct the claim (for a whole-body study, 78813 plus the diagnostic CT code with the modifier) instead of appealing.

A Note on Appropriate Use Criteria

Older guidance says Medicare advanced imaging claims need an Appropriate Use Criteria consultation. That is no longer true: CMS paused the AUC program and rescinded its regulations in the CY 2024 Physician Fee Schedule final rule. Do not cite AUC in a Medicare appeal, and do not accept missing AUC as a Medicare denial reason. A commercial plan's own imaging guidelines are a separate matter.

Documentation Checklist

Order and indication

• ☐ Order naming the cancer or suspected cancer and the clinical question
• ☐ Whether the scan informs initial or subsequent treatment strategy (this drives PI or PS)
• ☐ Pathology report, or the prior imaging or tests that make the tumor strongly suspected

The study

• ☐ Report documenting the field of view (head to feet for 78816)
• ☐ Physician note explaining why the whole-body field was needed
• ☐ Tracer name and HCPCS code (A9552 for FDG)
• ☐ For a separately billed diagnostic CT: its own order, how it was acquired, and its own report

Coverage and authorization

• ☐ Authorization number, the code or codes it covers, and its dates
• ☐ For subsequent-strategy scans: dates of prior PET scans for the same cancer and the date initial therapy ended
• ☐ For a fourth or later subsequent scan (Medicare): documentation that meets your MAC's criteria for KX
• ☐ Signed ABN, if one was obtained

Denial paperwork

• ☐ Remittance showing the CARC, RARC and group code
• ☐ Denial notice naming the policy applied and the appeal deadline

Sample Appeal Language

Fill the brackets only with what the chart supports.

Covered Medicare indication (Traditional Medicare or Medicare Advantage)
"The PET/CT performed on [date] was ordered to inform the [initial / subsequent] treatment strategy for [cancer], which is [biopsy-proven per pathology dated (date) / strongly suspected based on (test) dated (date)]. NCD 220.6.17 nationally covers FDG PET for this purpose. The claim was billed with modifier [PI / PS] and tracer code A9552. [For Medicare Advantage: under 42 CFR 422.101(b)(1), the plan must comply with national coverage determinations.]"

Whole-body field of view
"The report dated [date] documents imaging from [the vertex] to [the feet]. The whole-body field was needed because [reason documented by the ordering physician, such as known or suspected disease in (location) outside the skull base to mid-thigh range]. The code billed, 78816, matches the study performed."

Fourth or later subsequent scan (Medicare)
"This is FDG PET scan number [4 or later] for subsequent treatment strategy for [diagnosis]. On [date], [physician] documented that [specific treatment decision] depends on this scan because [reason]. This documentation meets [MAC]'s criteria for coverage beyond three scans as published in [article or LCD]."

Commercial medical necessity
"[Plan] denied this study under [policy name, number and version date]. Criterion [X] requires [criterion]. The record meets it: [chart citation with page number]."

Filing Deadlines and Appeal Routes

Read the denial notice first. It states the deadline that applies to that claim.

Traditional Medicare

• Redetermination by the MAC within 120 days of receiving the initial determination (receipt is presumed 5 days after the notice date).
• Reconsideration by a Qualified Independent Contractor within 180 days of receiving the redetermination.
• Then an ALJ hearing (60 days), the Medicare Appeals Council (60 days) and federal court (60 days). The ALJ and federal court levels have amount-in-controversy thresholds that change every year.
• A claim returned with MA130 has no appeal rights. Correct it and submit a new claim.

Medicare Advantage

• The enrollee, or a non-contracted provider with a waiver of liability, requests plan reconsideration within 65 days of the notice (42 CFR 422.582).
• If the plan upholds the denial, it is forwarded automatically to the Independent Review Entity.
• Standard pre-service reconsiderations are decided within 30 days, payment reconsiderations within 60 days, and expedited ones within 72 hours.
• Contracted providers' payment disputes follow their contract.

Commercial and ERISA group health plans

• On ACA-compliant plans, the member, or the provider as authorized representative, has at least 180 days from the adverse benefit determination to file an internal appeal.
• Provider appeals under a participation contract follow the contract. Those windows vary, commonly 60 to 180 days and sometimes 365, so check the contract and the denial notice.

Medicaid

• Appeal windows vary by state and by managed care plan.

When to Request External Review

External review is for denials based on medical judgment, such as medical necessity, after the internal appeals are exhausted. Under the federal process for commercial and ERISA plans, the request is due within 4 months of the final internal denial; state external review processes vary. Standard decisions come within 45 days and expedited ones within 72 hours. The decision binds that claim only and does not set precedent for the next 78816 claim.

Request it when the plan's reason is clinical (the scan was not needed, or the whole-body field was not needed) and the chart answers that reason. It is the wrong route for coding problems such as a missing PI, PS or KX modifier, a missing tracer code or a bundled CT line. Fix those on the claim.

For Medicare Advantage, the Independent Review Entity step happens automatically when the plan upholds its denial. For Traditional Medicare, the independent step is the QIC reconsideration.

If you work PET/CT denials from 835 files, EZAppeal sorts the denials on an 835 into next steps for free, and drafts appeal and prior authorization letters in a few minutes, citing the payer's policy when one is on file, for your team to review and send. Every account signs a BAA, and new accounts get 6 free documents.